特应性皮炎（AD）前沿文献精读特辑（J Dermatol）
深度精选：特应性皮炎非药物心身医学干预策略：日本专家德尔菲共识解析 等 1 篇重磅文献
系统精读发表于 J Dermatol 等顶刊的特应性皮炎最新重磅研究：涵盖 临床研究型、基础研究型 等前沿维度，解析核心靶点、循证数据与一线转化启示。
【特应性皮炎前沿快报】 本期精选今日全球顶尖医学期刊发表的重磅特应性皮炎（AD）研究成果。涵盖基础免疫病理与临床靶向治疗前沿，助力把握 AD 疾病生物学与个体化诊疗脉搏。
📑 本期文献快速导航
- 1. 《J Dermatol》特应性皮炎非药物心身医学干预策略：日本专家德尔菲共识解析
前沿综述与指南· 核心靶点：大脑-皮肤轴（Brain-Skin Axis）与神经-免疫-内分泌网络调控；靶向心理应激诱…
1. 《J Dermatol》特应性皮炎非药物心身医学干预策略：日本专家德尔菲共识解析
英文原题: Non-Pharmacological Psychosomatic Approaches to Patients With Atopic Dermatitis: A Delphi Consensus of Expert Opinions in Japan
发表期刊: The Journal of dermatology (J Dermatol) | 影响因子: 3.4 (3区)
文献检索: PubMed: 42838757 · DOI: 10.1111/1346-8138.70523
研究分类: 前沿综述与指南 | 标签: #前沿综述与指南 #J Dermatol #特应性皮炎 #德尔菲共识 #心身医学 #大脑-皮肤轴
📌 核心定论 / Core Conclusion
本项日本心身皮肤病学德尔菲共识研究首次系统规范了特应性皮炎（AD）的非药物心身医学诊疗路径。专家组在建立“生物-心理-社会（BPS）”共识模型、识别“成瘾性搔抓”神经行为恶性循环、强化医患治疗同盟以及实施团体心理治疗等25项关键陈述上达成高度一致（≥75%共识度）。该共识为打破特应性皮炎“瘙痒-搔抓-神经神经内分泌紊乱”提供了标准化的非药物整合干预范式。
🔬 研究方法与样本 / Design
改良德尔菲法专家共识研究（两轮调查，首轮21名专家中17名回复[81.0%]，次轮17名专家100%回复，共纳入29项评估条目）
🎯 机制与靶点 / Mechanism & Target
大脑-皮肤轴（Brain-Skin Axis）与神经-免疫-内分泌网络调控；靶向心理应激诱导的下丘脑-垂体-肾上腺（HPA）轴功能紊乱、交感神经肽释放及神经源性瘙痒/搔抓中枢敏化通路
📊 核心数据与关键发现
- 专家响应率与采纳率：首轮响应率81.0%（17/21），第二轮响应率100%（17/17），在涵盖的29项陈述中最终达成共识并采纳25项（共识阈值预设为赞同率≥75%）。
- 病理评估与BPS模型构建：将病理评估拓展至“生理-心理”双重视角（包括成瘾性搔抓评估、生物-心理-社会[BPS]模型建立与病理生理学假说拟定）获得超高水平专家共识。
- 医患同盟与认知重塑：规范了病史采集、体格检查、肯定患者疾病应对努力以及尊重患者疾病解释模型的临床流程，证实间接引导患者自我识别AD加重诱因具备高度可行性与一致性。
- 治疗转化与团体干预：共14项关于将心身相关性应用于临床治疗的陈述达成共识；第二轮中“团体心理治疗（Group Therapy）”作为有效的心身非药物干预措施正式获得专家共识推荐。
💡 专家深度评析与转化启示
在以靶向生物制剂（如抗IL-4Rα、抗IL-13、抗IL-31RA抗体）和JAK抑制剂为主导的精准免疫治疗时代，心身诱因与神经中枢敏化导致的“心因性/成瘾性搔抓”常成为难治性皮损残留和复发的关键瓶颈。本共识强调了“大脑-皮肤轴”在特应性皮炎全程管理中的核心地位，填补了一线临床在非药物心理干预路径缺乏循证共识的空白。
该研究提示临床皮肤科医师：在实施标准抗炎与屏障修复的同时，应常规引入BPS模型评估患者心理应激、隐匿性成瘾性搔抓行为，并适时联合认知行为疗法、放松训练及团体干预，从而实现“免疫精准靶向”与“心身神经行为重塑”的协同增效，显著改善难治性AD患者的长期疾病转归与生活质量。
展开查看英文原始摘要 (Original Abstract)
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by persistent itch and a prolonged clinical course and can affect mental health and impair quality of life. Stress and anxiety exacerbate the symptoms of itch, leading to a vicious cycle that influences patient scratching behaviors and worsens disease prognosis. Dermatologists should consider psychosomatic correlations in patients with AD and provide psychosomatic intervention. However, standardized, consensus-based non-pharmacological psychosomatic approaches for patients with AD have not been established in Japan. This study sought to establish a Japanese consensus on non-pharmacological psychosomatic approaches to patients with AD. Japanese experts in psychosomatic dermatology stated their level of agreement with 28 items in round 1 plus one added in round 2 (29 items in total) regarding psychosomatic approaches as non-pharmacological approaches among patients with AD over Delphi rounds. Consensus was defined a priori as agreement from ≥ 75% of participants. The response rate was 17/21 (81.0%) in the first round and 17/17 (100%) in the second round. Twenty-five statements were adopted over both rounds. Performance of medical interviews and physical examinations, recognition of patient efforts, and respect for the interpretive model of the patient categorized to establish a good therapeutic relationship showed agreement. Evaluation of pathology from physical and psychological perspectives (addictive scratching, building a bio-psycho-social [BPS] model and pathophysiological hypothesis) showed high-level agreement. Indirectly promoting patient awareness of aggravating factors of AD and sharing the BPS model and pathophysiological hypothesis with the patient showed consensus. Further, 14 statements about the application of psychosomatic correlations to therapy showed agreement. In the second round, group therapy also gained consensus as a useful intervention. Our Delphi panel provides recommendations about psychosomatic interventions for patients with AD to standardize approaches in clinical practice and research.